Penka S. Petrova

发表

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

I. Flinn, K. Savage, M. Minden, 2021, Clinical Cancer Research.

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets

V. Lee, Tran Truong, M. Wong, 2017, PloS one.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

S. Trudel, J. Koropatnick, S. Viau, 2016, Clinical Cancer Research.

MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons.

David I. Smith, J. Pevsner, J. Kelly, 2003, Journal of molecular neuroscience : MN.

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.

O. Akilov, C. Querfeld, John A Thompson, 2021, The Lancet. Haematology.

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

O. Akilov, C. Querfeld, R. Pillai, 2018, Blood.

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal

O. Akilov, C. Querfeld, R. Pillai, 2017 .

Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model

G. Lin, L. D. Johnson, Bolette Bossen, 2017 .

Abstract 2653: The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor

V. Lee, G. Lin, L. D. Johnson, 2017 .

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

I. Flinn, M. Maris, S. Ansell, 2016 .

Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models

J. Koropatnick, R. Figueredo, S. M. Vareki, 2018, Immunology.

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

M. Maris, A. Lesokhin, Catherine Lai, 2021, Blood.

Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases.

David I. Smith, J. Pevsner, J. Kelly, 2004, Progress in brain research.

A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.

O. Akilov, C. Querfeld, L. Johnson, 2017 .

David I. Smith, J. Pevsner, J. Kelly, 2007, Journal of Molecular Neuroscience.

Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial

O. Akilov, C. Querfeld, R. Pillai, 2018, European Journal of Cancer.

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

B. Cheson, M. Maris, A. Lesokhin, 2020 .